Anika Therapeutics, Inc.

What they do

Anika sells HA-based products for OA pain management and regenerative tissue repair. It generates revenue through three customer types: commercial partnerships such as J&J MedTech, hospitals and ambulatory service centers, and distributors. The company sold Arthrosurface in October 2024 and Parcus Medical in March 2025 to concentrate on OA Pain Management and Regenerative Solutions, led by Monovisc, Orthovisc, Cingal, and the Integrity Implant System.

Revenue drivers

• OEM/commercial partnership channel — Anika is the exclusive supplier of Orthovisc and Monovisc to J&J MedTech under contracts from 2003 and 2011; J&J MedTech represented 50% of total revenues for the year ended December 31, 2025.
• Commercial Channel (direct sales) — Direct sales to hospitals, ambulatory service centers, and distributors; the second quarter of 2026 set a record at $13.9 million, up 17% year-over-year organically.
• Integrity Implant System — A HA-based scaffold for rotator cuff and other tendon repairs within the Regenerative Solutions portfolio; the company cites continuing growth in surgeries and adoption by new customers.
• International OA Pain Management — International sales of the OA Pain Management portfolio, led by Monovisc and Cingal; the second quarter of 2026 was described as a record quarter for international revenue.

Recent performance

Second quarter 2026 total revenue was $32.6 million versus $28.2 million in the prior-year period, with record Commercial Channel revenue of $13.9 million, up 17% organically. Gross profit was $21.2 million versus $14.4 million, and gross margin expanded to 65%. Operating expenses were $18.3 million, or $17.5 million excluding about $0.8 million of one-time severance costs. Net income was $3.3 million, a 10% margin, and adjusted EBITDA was $7.1 million, a 22% margin and the highest since 2020. Full-year 2025 revenue was $112.8 million with net loss of $11.0 million, and operating cash flow was $11.2 million.

Strategy

Anika shifted strategy in October 2024 to focus on OA Pain Management and Regenerative Solutions, selling Arthrosurface and Parcus Medical. It is emphasizing commercial execution of the Integrity Implant System and investing in a regenerative medicine pipeline. It submitted a PMA application for Hyalofast on October 31, 2025, and received an FDA deficiency letter in January 2026 to which it is preparing a response. For Cingal, it is advancing a bioequivalence study for Triamcinolone Hexacetonide and CMC work toward an NDA, while engaging the FDA on a U.S. approval path.

Risks

• Customer concentration — J&J MedTech accounted for 50% of total revenues for the year ended December 31, 2025, so loss or reduction of that relationship would materially affect results.
• Regulatory approval uncertainty — The FDA identified deficiencies in the Hyalofast PMA in January 2026, and the timing of U.S. approval for Hyalofast and Cingal remains uncertain.
• Historical losses and revenue decline — Annual revenue fell from $147.8 million in 2021 to $112.8 million in 2025, with net losses in each year from 2022 through 2025.
• OEM order timing — Management expects some moderation in revenue and profitability in the second half of 2026 relative to the first half due to the timing of certain OEM orders.

Outlook

Management raised full-year 2026 guidance, including an adjusted EBITDA margin outlook of 13%-17%, citing favorable OEM trends, Commercial Channel growth, and cost discipline. It expects some moderation in revenue and profitability in the second half of 2026 versus the first half due to OEM order timing. The company adopted a new guidance practice of forecasting only revenue from products with regulatory approval or clearance, so 2027 Commercial Channel revenue guidance no longer includes unapproved products. It continues FDA discussions on Hyalofast co-primary endpoints and Cingal NDA preparations.